Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
The Journal of Rheumatology|January 17, 2018
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic ArthritisFaekah Gohar, Janneke Anink, Halima Moncrieffe, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Arthritis Research & Therapy|August 8, 2015
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritisJanneke Anink, Lisette W A Van Suijlekom-Smit, Marieke H Otten, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?Marieke H Otten, Femke H M Prince, Rebecca Ten Cate, et al.
Rheumatology (Oxford, England)|January 7, 2020
MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritisAnouk M Barendregt, Saskia R Veldkamp, Petra C E Hissink Muller, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Pageof 6